Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor ModelsXiaochun Zhang, Dana C Borcherding, Minjie Zhang, et al.
Clinical Pharmacology and Therapeutics|December 3, 2020
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry PerspectiveTycho Heimbach, Yuan Chen, Jun Chen, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2018
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current LandscapeMarjoleen J M A Nijsen, Fan Wu, Loveleena Bansal, et al.
Journal of Medicinal Chemistry|April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted CancersKevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Drug Discovery Today|May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspectiveHarvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of InfluenzaUpul K Bandarage, Michael P Clark, Emanuele Perola, et al.
The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2Luc J Farmer, Michael P Clark, Michael J Boyd, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Pageof 5